Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30127% above fair value
$21.73−0.98 (-4.32%)
Close on Nov 20, 2026Market cap $3.66BP/E –Yield –
Tango Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Tango Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$144.25M. For fiscal 2025 it was -$139.93M. The highest annual figure on record is $68.97M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$139.93M | – |
| FY2024 | Dec 31, 2024 | -$132.26M | – |
| FY2023 | Dec 31, 2023 | -$119.51M | – |
| FY2022 | Dec 31, 2022 | -$116.77M | – |
| FY2021 | Dec 31, 2021 | -$61.36M | -189.0% |
| FY2020 | Dec 31, 2020 | $68.97M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$38.85M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$29.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.10M | – |
| Q2 FY2025 | Jun 30, 2025 | -$37.14M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.69M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.35M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.60M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.27M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.78M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.52M | – |
See a number that looks wrong?